Leucovorin Calcium

Folic Acid Deficiency, Anemia, Megaloblastic, Anemia, Macrocytic + 15 more

Treatment

3 FDA approvals

20 Active Studies for Leucovorin Calcium

What is Leucovorin Calcium

Leucovorin

The Generic name of this drug

Treatment Summary

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is a medication used to counteract the effects of certain cancer treatments, such as methotrexate, which inhibit the enzyme dihydrofolate reductase (DHFR). It is also used to treat megaloblastic anemias and in combination with 5-fluorouracil to prolong survival in patients with advanced colorectal cancer. Folinic Acid is a form of folic acid, a B vitamin required for the synthesis of DNA and proteins. It is available in two

Leucovorin Calcium

is the brand name

image of different drug pills on a surface

Leucovorin Calcium Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Leucovorin Calcium

Leucovorin

1987

65

Approved as Treatment by the FDA

Leucovorin, also known as Leucovorin Calcium, is approved by the FDA for 3 uses like Advanced Colorectal Cancer and methotrexate toxicity .

Advanced Colorectal Cancer

Used to treat Advanced Colorectal Cancer in combination with Fluorouracil

methotrexate toxicity

Colorectal Carcinoma

Used to treat Advanced Colorectal Cancer in combination with Fluorouracil

Effectiveness

How Leucovorin Calcium Affects Patients

Leucovorin is a form of folic acid that is used to counteract the effects of drugs that block folic acid. Its active component is (-)-folinic acid, which does not need to be reduced by an enzyme in order to be used. Leucovorin is given to reduce the therapeutic and toxic effects of drugs like methotrexate and to make other drugs like fluorouracil more effective.

How Leucovorin Calcium works in the body

Leucovorin is a form of folic acid and is used to increase levels of folic acid when it has been blocked by other drugs, like methotrexate. It also helps a drug called fluorouracil work better by reinforcing the bond that allows it to attach to an enzyme called thymidylate synthetase.

When to interrupt dosage

The recommended dosage of Leucovorin Calcium is contingent upon the diagnosed condition, such as Macrocytic anemia, Anemia of Pregnancy and Bladder Cancer. The amount of dosage varies, as per the administration technique (e.g. Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous or Tablet) presented in the following table.

Condition

Dosage

Administration

Pancreatic Neoplasms

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Stomach Neoplasms

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Colorectal Carcinoma

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Esophageal Neoplasms

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Anemia

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

HIV

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

methotrexate toxicity

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Bladder Cancer

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Anemia of Pregnancy

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

normochromic anemia

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Folic Acid Deficiency

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Anemia, Megaloblastic

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Anemia, Macrocytic

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

folic acid

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

pyrimethamine

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Anemia, Hypochromic

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Iron deficiency

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

folate

, 10.0 mg/mL, 5.0 mg, 25.0 mg, 15.0 mg, 10.0 mg, 2.5 mg, 20.0 mg, 350.0 mg, 50.0 mg, 35.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 1.0 mg, 3.0 mg, 3.5 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intramuscular; Intravenous, Solution, Liquid, Liquid - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Solution - Intravenous, Intravenous, Tablet, chewable, Tablet, chewable - Oral, Kit, Injection, Injection - Intramuscular; Intravenous, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Liquid - Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular; Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Warnings

There are 20 known major drug interactions with Leucovorin Calcium.

Common Leucovorin Calcium Drug Interactions

Drug Name

Risk Level

Description

5-fluorouridine

Major

The risk or severity of adverse effects can be increased when Leucovorin is combined with 5-fluorouridine.

Capecitabine

Major

The risk or severity of adverse effects can be increased when Leucovorin is combined with Capecitabine.

Doxifluridine

Major

The risk or severity of adverse effects can be increased when Leucovorin is combined with Doxifluridine.

Flucytosine

Major

The risk or severity of adverse effects can be increased when Leucovorin is combined with Flucytosine.

Fluorouracil

Major

The risk or severity of adverse effects can be increased when Leucovorin is combined with Fluorouracil.

Leucovorin Calcium Toxicity & Overdose Risk

The lowest toxic dose of leucovorin in rats is over 8000mg/kg when taken orally. Taking too much leucovorin may reduce the effectiveness of drugs that block folic acid.

image of a doctor in a lab doing drug, clinical research

Leucovorin Calcium Novel Uses: Which Conditions Have a Clinical Trial Featuring Leucovorin Calcium?

262 active clinical trials are assessing the potential of Leucovorin Calcium in providing relief from Pancreatic Metastatic Cancer, Anemia of Pregnancy and Colorectal Carcinoma.

Condition

Clinical Trials

Trial Phases

folic acid

0 Actively Recruiting

Anemia of Pregnancy

1 Actively Recruiting

Phase 4

Anemia

0 Actively Recruiting

Stomach Neoplasms

1 Actively Recruiting

Not Applicable

normochromic anemia

0 Actively Recruiting

Bladder Cancer

100 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1

Anemia, Megaloblastic

0 Actively Recruiting

Esophageal Neoplasms

0 Actively Recruiting

HIV

155 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

methotrexate toxicity

0 Actively Recruiting

Anemia, Macrocytic

0 Actively Recruiting

Iron deficiency

6 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Early Phase 1, Phase 3

pyrimethamine

0 Actively Recruiting

folate

0 Actively Recruiting

Folic Acid Deficiency

0 Actively Recruiting

Pancreatic Neoplasms

27 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3

Colorectal Carcinoma

0 Actively Recruiting

Anemia, Hypochromic

1 Actively Recruiting

Phase 2

Leucovorin Calcium Reviews: What are patients saying about Leucovorin Calcium?

3.7

Patient Review

8/11/2009

Leucovorin Calcium for High Blood Levels of Methotrexate

I originally took this medication orally, but had to switch to injections because of stomach problems. The leucovorine helped somewhat, but I still needed the injection in order to get relief.

2

Patient Review

7/13/2012

Leucovorin Calcium for High Blood Levels of Methotrexate

I haven't felt any benefits from this yet. Not sure if it's worth continuing.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about leucovorin calcium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is leucovorin calcium a chemo drug?

"Leucovorin is not a chemotherapy medication, but can be given alongside chemotherapy to enhance its effects. For example, it is often used in conjunction with the chemotherapy medication fluorouracil (5-FU)."

Answered by AI

Does leucovorin have side effects?

"It is possible to have an allergic reaction to Leucovorin, which may cause a rash, itching, and facial flushing. These side effects are rare and usually not severe. Nausea and vomiting are also possible side effects, but are even rarer."

Answered by AI

What is leucovorin calcium used for?

"The purpose of this medication is to either treat or prevent serious blood cell disorders that are caused by certain drugs."

Answered by AI

Is leucovorin calcium the same as folic acid?

"Folic acid is a type of folate that does not require metabolism by dihydrofolate reductase in order to be active. Folic acid antagonists are a type of chemotherapeutic drug that target this molecule."

Answered by AI

Clinical Trials for Leucovorin Calcium

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Image of Johns Hopkins Hospital in Baltimore, United States.

Intravenous Fluids for Bladder Cancer

18+
All Sexes
Baltimore, MD

Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operatively, which is an accepted standard practice, is beneficial. This study is a single institution randomized controlled trial where patients who choose to undergo radical cystectomy for bladder cancer will be randomized to an Enhanced Recovery After Surgery (ERAS) protocol with a home IVF program, consisting of 1 liter (L) of crystalloid fluid three times per week for four weeks, or ERAS protocol alone. The primary outcome will be 90-day hospital re-admissions, with secondary outcomes including 30 and 90 day complications.

Recruiting
Has No Placebo

Johns Hopkins Hospital

Max Kates, MD

Have you considered Leucovorin Calcium clinical trials?

We made a collection of clinical trials featuring Leucovorin Calcium, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

Waitlist Available
Has No Placebo

Los Angeles General Medical Center

Hayoun Lee, PhD

Image of Columbia University Irving Medical Center in New York, United States.

Intravenous Iron for Iron Deficiency in Scoliosis

10 - 19
All Sexes
New York, NY

Adolescents and young adults undergoing spinal fusion surgery for the correction of scoliosis and other spinal deformity are at high risk of perioperative iron deficiency and anemia, yet the means and evidence for optimizing iron status have not been described in this setting. The proposed study is a randomized controlled trial of preoperative intravenous iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in this vulnerable population. Building evidence for patient blood management interventions such as iron supplementation is vital to ensuring high quality care of surgical patients and may reduce unnecessary transfusions amid recent blood shortages.

Phase 2 & 3
Recruiting

Columbia University Irving Medical Center

Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Have you considered Leucovorin Calcium clinical trials?

We made a collection of clinical trials featuring Leucovorin Calcium, we think they might fit your search criteria.
Go to Trials
Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Leucovorin Calcium clinical trials?

We made a collection of clinical trials featuring Leucovorin Calcium, we think they might fit your search criteria.
Go to Trials